ArticleJournal of inflammation research2025
Fecal Calprotectin Combined with Blood Inflammatory Biomarkers Enhances Diagnostic Evaluation and Supports Mucosal Healing Assessment in Pediatric Crohn's Disease.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Previous small-sample study suggested that fecal calprotectin (FC) combined with blood inflammatory biomarkers may aid in Crohn's disease (CD) diagnosis. This study aimed to validate the FC's diagnostic and mucosal healing assessment value of FC and a noninvasive composite index in pediatric CD. Patients and Methods: Patients aged 2-17 years who underwent ileocolonoscopy for suspected or established CD were enrolled. Based on endoscopy, participants were classified into three groups: controls (functional gastrointestinal disorders), MH (mucosal healing, SES-CD <3, indicating minimal or absent visible inflammation), and ML (mucosal lesions, SES-CD ≥3). Fecal and blood samples were collected before endoscopy. Group differences were assessed using Kruskal-Wallis/Dunn's tests; correlations were evaluated via Spearman coefficients; ROC analysis was used to assess diagnostic performance. A composite index was constructed by weighting CRP, ESR, and IL-6 based on their correlations with FC. Results: Among 123 participants, FC levels significantly differed across groups (P < 0.001), highest in patients with mucosal lesions. For distinguishing CD from controls, FC showed limited accuracy (AUC = 0.651), while the composite index improved performance (AUC = 0.754). In established CD, FC alone showed strong ability to differentiate mucosal healing from active disease (AUC = 0.888), with a slight improvement using the composite index (AUC = 0.921). Conclusion: The composite index integrating FC with inflammatory markers improves diagnostic performance over FC alone for distinguishing CD from controls and slightly enhances mucosal healing assessment, supporting its potential utility as a practical noninvasive tool for clinical monitoring in pediatric CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.